alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET AS OF MARCH 31, 1997 AND THE INCOME STATEMENT FOR THE THREE MONTHS ENDED
MARCH 31, 1997, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                              16
<SECURITIES>                                         0
<RECEIVABLES>                                      321
<ALLOWANCES>                                         0
<INVENTORY>                                        261
<CURRENT-ASSETS>                                   646
<PP&E>                                             225
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                   1,273
<CURRENT-LIABILITIES>                              372
<BONDS>                                            305
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                         398
<TOTAL-LIABILITY-AND-EQUITY>                     1,273
<SALES>                                            527
<TOTAL-REVENUES>                                   527
<CGS>                                              380
<TOTAL-COSTS>                                      380
<OTHER-EXPENSES>                                   (2) 
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   6
<INCOME-PRETAX>                                     20
<INCOME-TAX>                                         9
<INCOME-CONTINUING>                                 11
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                        11
<EPS-PRIMARY>                                      .53
<EPS-DILUTED>                                      .53
        

</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF SCIENTIFIC GAMES, INC. FOR THE NINE MONTH PERIOD ENDED
SEPTEMBER 30, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               SEP-30-1999
<EXCHANGE-RATE>                                  1,000
<CASH>                                          13,665
<SECURITIES>                                         0
<RECEIVABLES>                                   47,528
<ALLOWANCES>                                       243
<INVENTORY>                                     14,323
<CURRENT-ASSETS>                                82,795
<PP&E>                                         126,027
<DEPRECIATION>                                  65,459
<TOTAL-ASSETS>                                 196,057
<CURRENT-LIABILITIES>                           49,853
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            12
<OTHER-SE>                                     128,063
<TOTAL-LIABILITY-AND-EQUITY>                   196,057
<SALES>                                        169,302
<TOTAL-REVENUES>                               169,302
<CGS>                                          108,364
<TOTAL-COSTS>                                  108,364
<OTHER-EXPENSES>                                35,182
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 405
<INCOME-PRETAX>                                 24,576
<INCOME-TAX>                                     8,765
<INCOME-CONTINUING>                             15,811
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    15,811
<EPS-BASIC>                                       1.33
<EPS-DILUTED>                                     1.32


</TABLE>
CURRENTLY AVAILABLE BIOLOGICS FOR FISH

The following is a list of currently available biologics for use in aquatic 

animals in the United States, with an active license status. This list includes

the True Name of the product, the Product Code, and the approved species for 

the product.

Elanco U.S. Inc., U.S. Veterinary Permittee No. 303A, 800 5th Street 

NW, Fort Dodge, IA 50501-7425

• Arthrobacter Vaccine, Live Culture, Product Code 1K11.00, for use in

salmonids

• Aeromonas Salmonicida-Vibrio Anguillarum-OrdaliiSalmonicida Bacterin, Product Code 2138.02, for use in salmonids

• Infectious Salmon Anemia Virus Vaccine, Killed Virus,

Aeromonas Salmonicida-Vibrio Anguillarum-OrdaliiSalmonicida Bacterin, Product Code 4A45.20, for use in salmonids

• Yersinia Ruckeri Bacterin, Product Code 2638.00, for use in salmonids

• Infectious Hematopoietic Necrosis Virus Vaccine, DNA, Product Code

17A5.D0, for use in salmonids

INTERVET INC., U.S. Veterinary License No. 165A, 21401 West Center 

Road, Elkhorn, NE 68022-2202

• Edwardsiella Ictalurii Vaccine, Avirulent Live Culture, Product Code

1531.00, for use in catfish

• Flavobacterium Columnare Vaccine, Avirulent Live Culture,

Product Code 17F1.00, for use in catfish

BOEHRINGER INGLEHEIM ANIMAL HEALTH USA INC., U.S. 

Veterinary License No. 124, 2621 North Belt Highway, St. Joseph, MO 

64506-2002 

• West Nile Virus Vaccine, Killed Virus, Product Code 1995.22, for use

in alligators

Last updated November, 2021
17172

#### GECC Financial Corp. v. Kalilikane; Associates Financial Services Co. of Hawaii, Inc. v. Kalilikane

April 16, 1997

Order No. 97-38

Dismissed
#### State v. Ortiz

22972

04/11/2001

Affirmed
CERTIFICATION PURSUANT TO
  1.
    
    I have reviewed this report on Form 10-Q for the quarterly period ended June 30, 2010 of
Belden & Blake Corporation;
 2.
    
    Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
 3.
    
    Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;
 4.
    
    The registrants other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)), for the registrant and have:
    5.
    
    The registrants other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrants auditors and the
audit committee of the registrants board of directors (or persons performing the equivalent
functions):
   Date: August 12, 2010
    By:
    /s/   James M. VanderhiderJames M. Vanderhider, President,Chief Financial Officer and Director
Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Indevus Pharmaceuticals, Inc. (the Company) on
Form 10-K for the period ended September 30, 2006 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Michael W. Rogers, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.



|                        |  |                         
|----------------------- |  | ------------------------
|                        | 
|By:                     |  | /s/    MICHAEL W.
ROGERS
|Chief Financial Officer
|December 7, 2006
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 07-4064

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

v.

JAMES M. ANDERSON, a/k/a Hollywood,

Defendant - Appellant.

On Remand from the Supreme Court of the United States.

(S. Ct. No. 07-7378)

Submitted: April 9, 2008 Decided: May 23, 2008

Before WILKINSON, TRAXLER, and DUNCAN, Circuit Judges.

Vacated and remanded by unpublished per curiam opinion.

Mary Lou Newberger, Federal Public Defender, Jonathan D. Byrne,

Appellate Counsel, Edward H. Weis, Assistant Federal Public

Defender, Charleston, West Virginia, for Appellant. Charles T.

Miller, United States Attorney, John L. File, Assistant United

States Attorney, Beckley, West Virginia, for Appellee. 

Unpublished opinions are not binding precedent in this circuit.
- 2 -

PER CURIAM:

James M. Anderson pled guilty to distributing a quantity

of cocaine base (crack), 21 U.S.C. § 841(a)(1) (2000), and was

sentenced to a term of 108 months imprisonment. Anderson appealed

his sentence, arguing that the district court erred by seeking to

impose a “reasonable” sentence rather than a sentence “sufficient,

but not greater than necessary” to comply with the purposes of 18

U.S.C.A. § 3553(a) (West 2000 & Supp. 2007), and failed to consider

adequately the effect of the 100:1 sentencing ratio for cocaine and

crack offenses in his case. He also claimed that his sentence was

greater than necessary to further the purposes of § 3553(a)(2). We

affirmed his sentence; however, the Supreme Court subsequently

vacated the judgment and remanded the case for reconsideration in

light of Kimbrough v. United States, 128 S. Ct. 558 (2007). See

United States v. Anderson, 241 F. App’x 912 (4th Cir. 2007),

vacated, 128 S. Ct. 913 (2008).

In Kimbrough, the Supreme Court held that “it would not

be an abuse of discretion for a district court to conclude when

sentencing a particular defendant that the crack/powder disparity

yields a sentence ‘greater than necessary’ to achieve § 3553(a)’s

purposes, even in a mine-run case.” Kimbrough, 128 S. Ct. at 575.

Kimbrough has thus abrogated United States v. Eura, 440 F.3d 625

(4th Cir. 2006) (holding that sentencing court may not vary from

guideline range solely because of 100:1 ratio for crack/cocaine
*

On remand, Anderson will be resentenced under the revised

guidelines for crack offenses that took effect on November 1, 2007.

- 3 -

offenses), vacated, 128 S. Ct. 853 (2008). The district court did

not have the benefit of Kimbrough when it determined Anderson’s

sentence. To give the district court the opportunity to reconsider

the sentence in light of Kimbrough, we conclude that resentencing

is necessary. 

We therefore vacate the sentence imposed by the district

court and remand for resentencing.* We dispense with oral argument

because the facts and legal contentions are adequately presented in

the materials before the court and argument would not aid the

decisional process.

VACATED AND REMANDED
[Federal Register Volume 88, Number 239 (Thursday, December 14, 2023)]
[Notices]
[Page 86686]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-27419]


-----------------------------------------------------------------------

POSTAL SERVICE


Product Change--Priority Mail Express, Priority Mail, and USPS 
Ground Advantage[supreg] Negotiated Service Agreement

AGENCY: Postal Service<SUP>TM</SUP>.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Postal Service gives notice of filing a request with the 
Postal Regulatory Commission to add a domestic shipping services 
contract to the list of Negotiated Service Agreements in the Mail 
Classification Schedule's Competitive Products List.

DATES: Date of required notice: December 14, 2023.

FOR FURTHER INFORMATION CONTACT: Sean C. Robinson, 202-268-8405.

SUPPLEMENTARY INFORMATION: The United States Postal Service[supreg] 
hereby gives notice that, pursuant to 39 U.S.C. 3642 and 3632(b)(3), on 
December 8, 2023, it filed with the Postal Regulatory Commission a USPS 
Request to Add Priority Mail Express, Priority Mail & USPS Ground 
Advantage[supreg] Contract 31 to Competitive Product List. Documents 
are available at www.prc.gov, Docket Nos. MC2024-107, CP2024-111.

Sean C. Robinson,
Attorney, Corporate and Postal Business Law.
[FR Doc. 2023-27419 Filed 12-13-23; 8:45 am]
BILLING CODE 7710-12-P
**Exhibit 11**

 

**IBIS TECHNOLOGY CORPORATION****STATEMENTRE:  COMPUTATION OF PER SHARE LOSS**
|                                                                              |   | **Years  Ended December 31,** |       |
|-----------------------------------------------------------------------------------|--------|-------------------------------|------------|
|                                                                              |   | **2001**                      |       | **2002** |   | **2003** |   |
|                                                                              |   |                          |       |   |   |   |   |
| Basic net loss                                                                    |   | $                             | (9,594,919 | ) | $ | (14,096,179 | ) | $ | (21,449,789 | ) |
| Weighted average common shares  outstanding-basic                                 |   | 8,378,262                     |       | 9,207,922 |   | 9,727,513 |   |
| Net additional common shares upon assumed  exercise of stock options and warrants |   | —                        |       | — |   | — |   |
| Weighted average commons shares  outstanding-diluted                              |   | 8,378,262                     |       | 9,207,922 |   | 9,727,513 |   |
| Net loss per common share                                                         |   |                          |       |   |   |   |   |
| Basic                                                                             |   | $                             | (1.15      | ) | $ | (1.53 | ) | $ | (2.21 | ) |
| Diluted                                                                           |   | $                             | (1.15      | ) | $ | (1.53 | ) | $ | (2.21 | ) |

 

1

----
April 14, 1998

19825

#### Makahiki Nui Management Corp. v. Curado

Affirmed
IV 

House Calendar No. 97 

114TH CONGRESS 

2D SESSION H. RES. 649 

[Report No. 114–458] 

Providing for consideration of the resolution (H. Res. 639) authorizing the 

Speaker to appear as amicus curiae on behalf of the House of Representatives in the matter of United States, et al. v. Texas, et al., No. 

15-674. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 16, 2016 

Mr. SESSIONS, from the Committee on Rules, reported the following resolution; which was referred to the House Calendar and ordered to be printed 

RESOLUTION 

Providing for consideration of the resolution (H. Res. 639) 

authorizing the Speaker to appear as amicus curiae on 

behalf of the House of Representatives in the matter 

of United States, et al. v. Texas, et al., No. 15-674. 

1 Resolved, That upon adoption of this resolution it 

2 shall be in order without intervention of any point of order 

3 to consider in the House the resolution (H. Res. 639) au4 thorizing the Speaker to appear as amicus curiae on behalf 

5 of the House of Representatives in the matter of United 


srobinson on DSK5SPTVN1PROD with BILLS
2 

•HRES 649 RH 

1 States, et al. v. Texas, et al., No. 15-674. The resolution 

2 shall be considered as read. The previous question shall 

3 be considered as ordered on the resolution to its adoption 

4 without intervening motion or demand for division of the 

5 question except: (1) one hour of debate equally divided and 

6 controlled by chair and ranking minority member of the 

7 Committee on Rules; and (2) one motion to recommit. 


srobinson on DSK5SPTVN1PROD with BILLS

srobinson on DSK5SPTVN1PROD with BILLS
House Calendar No. 97 

114TH CONGRESS 

2D SESSION H. RES. 649 

[Report No. 114–458] 

RESOLUTION 

Providing for consideration of the resolution (H. 

v. Texas, et al., No. 15-674. resentatives in the matter of United States, et al. amicus curiae on behalf of the House of RepRes. 639) authorizing the Speaker to appear as 

MARCH 16, 2016 

Referred to the House Calendar and ordered to be 

printed 


srobinson on DSK5SPTVN1PROD with BILLS
```

[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 901 Engrossed in House (EH)]

<DOC>
H. Res. 901

                In the House of Representatives, U. S.,

                                                    September 28, 2016.
    Resolved, That upon adoption of this resolution it shall be in order to take 
from the Speaker's table the bill (H.R. 5325) making appropriations for the 
Legislative Branch for the fiscal year ending September 30, 2017, and for other 
purposes, with the Senate amendment thereto, and to consider in the House, 
without intervention of any point of order, a motion offered by the chair of the 
Committee on Appropriations or his designee that the House concur in the Senate 
amendment. The Senate amendment and the motion shall be considered as read. The 
motion shall be debatable for one hour equally divided and controlled by the 
chair and ranking minority member of the Committee on Appropriations. The 
previous question shall be considered as ordered on the motion to adoption 
without intervening motion.
            Attest:

                                                                          Clerk.
```
CENTER FOR VETERINARY BIOLOGICS NOTICE NO. 15-06

TO: Biologics Licensees, Permittees, and Applicants

Directors, Center for Veterinary Biologics

Veterinary Services Leadership Team

FROM: Byron Rippke

Director

SUBJECT: Availability of Canine Influenza Virus Subtype H3N2

I. PURPOSE

The purpose of this notice is to inform interested parties that samples of a canine 

influenza virus (CIV) isolate are available for purchase from the National Veterinary 

Services Laboratories’ (NVSL) on-line catalog.

II. BACKGROUND

Canine influenza is a highly contagious infection caused by CIV. The causative CIV 

strains have been classified as H3N8 and H3N2 based on two surface proteins, 

hemagglutinin (HA) and neuraminidase (NA). The H3N2 CIV strain appeared to be 

limited to Korea, China, and Thailand until recently, when a CIV outbreak in the 

Chicago, Illinois, area was determined to be due to an H3N2 strain.

The CIV available from the NVSL was isolated from a nasal swab of a dog from 

Illinois in April 2015. Veterinary Services is making this virus available to the 

public without restrictions to encourage disease research and development of 

vaccines and diagnostic test kits to benefit the United States’ companion animal 

industry. It is expected that any master seeds derived from this isolate be tested 

according to title 9, Code of Federal Regulations, in the same way that any other

influenza master seed candidate would be tested.

III. ACTION (or POLICY)

Biologics firms wishing to obtain samples of the CIV isolate for research purposes 

should:

A. Complete a “Reagent Request Form,” VS Form 4-9, and submit it to the 

NVSL, along with the current user fee and shipping charges. The form can be 

obtained by any one of the following methods:

1. Access NVSL’s homepage at www.aphis.usda.gov/nvsl and click on

“Reagents and Proficiency Testing.”

Animal and Plant

Health Inspection

Service

Veterinary Services

Center for Veterinary 

Biologics

1920 Dayton Avenue

PO Box 844

Ames, IA 50010

(515) 337-6100

An Equal Opportunity Provider and Employer

BYRON 

RIPPKE

Digitally signed by BYRON RIPPKE 

DN: c=US, o=U.S. Government, 

ou=Department of Agriculture, cn=BYRON 

RIPPKE, 

0.9.2342.19200300.100.1.1=120010000040

93 

Date: 2015.05.12 10:57:53 -05'00'
CENTER FOR VETERINARY BIOLOGICS NOTICE NO. 15-06

Page 2

2. Contact the NVSL Reagents Office at Box 844, Ames, IA 50010, by mail.

3. Request a form by FAX at (515) 337-7402.

4. Request a form by email to NVSL_concerns@aphis.usda.gov.

B. The completed VS Form 4-9, and the payment associated with the order, may be 

submitted by one of the following methods:

1. By mail:

2. By email:

NVSL User Fees, Box 844, Ames, IA 50010

NVSL_concerns@aphis.usda.gov

C. Additional guidance regarding placing an order is available at the NVSL catalog

website or by telephone at (515) 337-6200.

D. A USDA permit is not currently required to receive this virus isolate.

IV. IMPLEMENTATION/APPLICABILITY

This reagent is currently available from the NVSL.

 An Equal Opportunity Provider and Employer
Infested Wheat Customs Inspections

KHAPRA

BEETLE

Adult

U.S. Customs and Border 

Protection officials 

inspect passenger 

baggage for Khapra 

beetle and other 

agricultural threats.

Khapra beetle and cast 

skins on grains of wheat 

Small, brown beetles 

in dried plant or 

animal products

Adults possess wings 

but aren't known to fly

Length between 2 and 3 millimeters 

(1 mm = thickness of 1 dime)
THEHARM IT CAUSES

This tiny beetle is one of the world’s most destructive 

pests of grain products and seeds. Its feeding 

damage often spoils 30 percent of the product; up to 

70 percent damage has been reported. Detections 

require massive, long-term, and costly control and 

eradication efforts. Established infestations are 

difficult to control because the beetle can survive 

without food for long periods, requires little moisture, 

hides in tiny cracks and crevices, and is relatively 

resistant to many insecticides and fumigants. 

WHAT YOU CAN DO • Find out if you’re traveling to a country where 

Khapra beetle is known to occur. Visit 

www.aphis.usda.gov/travel to view a travel 

alert that lists these countries.

• Don’t bring rice, soybeans, Cicer species 

(e.g., chickpeas), and safflower seeds from these 

countries into the United States. Check the 

Web site above for any updates.

• Report any sightings of this pest in imported 

food at HungryPests.com.

For more information, visit: 

HUNGRYPESTS.COM

United States Department of Agriculture

Animal and Plant Health Inspection Service

The U.S. Department of Agriculture is an equal opportunity provider and employer. 

 Program Aid No. 2125-KB Issued February 2013

WHAT TO LOOK FOR • Small brown beetles, larvae, 

or cast skins infesting grain, 

dried food, and cereal 

products, particularly wheat, 

barley, oats, rye, maize, rice, 

flour, malt, and noodles

• Similar infestation signs on 

almost any dried animal 

matter, including dog food

Khapra beetle larva inside 

plastic bag filled with rice